Remdesivir for COVID-19 | Bacterial vaginosis | Pain suppression

Early results show benefit of remdesivir for COVID-19; beneficial bacteria prevent recurring bacterial vaginosis; pain-suppression in brain

June 2, 2020 Edition COVID-19 is an emerging, rapidly evolving situation, and we at NIH are doing everything we can toward the development of diagnostics, therapeutics, and vaccines. You can find the latest public health information from CDC at www.coronavirus.gov and the latest research information from NIH at www.nih.gov/coronavirus. Meanwhile, science continues to progress on many other fronts, and we will continue to try to bring you stories across a wide range of topics. Early results show benefit of remdesivir for COVID-19 Early clinical trial results support the use of remdesivir for patients with severe COVID-19 who require supplemental oxygen, but more research is needed to improve outcomes for people with COVID-19. Beneficial bacteria prevent recurring bacterial vaginosis An experimental treatment for a common infection called bacterial vaginosis significantly reduced the rates of recurrence. Scientists find new pain-suppression center in the brain Scientists identified a group of neurons in mice that blunt pain within the brain. Such neurons could be promising targets for new non-addictive therapies for chronic pain. Popular Stories Novel coronavirus structure reveals targets for vaccines and treatments Study suggests new coronavirus may remain on surfaces for days Llama antibody engineered to block coronavirus How stress causes gray hair Poor sleep linked with higher blood sugar levels in African Americans Connect with Us Facebook RSS Feed Update Your E-mail Address | Add Subscriptions | Unsubscribe If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health. NIH…Turning Discovery Into Health®      This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612